Study summary · research use only
Cathelicidin LL-37 Ignites Primed NLRP3 Inflammasomes in Rosacea
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This study, combining in vitro human work and an in vivo murine model, reports that cathelicidin LL-37 promotes NLRP3-mediated inflammasome activation via lysosomal destabilization in lipopolysaccharide (LPS)- and UV-primed rosacea models, and that injecting LL-37 in the murine model produced skin inflammation that was reduced by direct NLRP3 inhibition or homozygous NLRP3 knockout.
Abstract
Microbes and commensal mites contribute to the development of inflammation and neurovascular dysregulation in rosacea. Cathelicidin family proteins are epithelial antimicrobial peptides expressed in higher-order mammals. In humans, mature LL-37 is cleaved from its precursor in response to microbial infection, UV light, and injury. In their new article in the Journal of Investigative Dermatology, Yoon et al. expand on existing evidence supporting LL-37 proinflammatory activity in lipopolysaccharide (LPS)- and UV-primed models of rosacea. They show in vitro that LL-37 promotes NLRP3-mediated inflammasome activation through lysosomal destabilization in the presence of LPS and that the injection of LL-37 in vivo leads to skin inflammation that is abrogated by direct NLRP3 inhibition and homozygous knockout in a murine model.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.